[Vitaprost plus in the treatment of chronic bacterial prostatitis].
Our study has demonstrated that compound medicine vitaprost plus in therapy of chronic bacterial prostatitis (CBP) reduces intensity of prostatic inflammation, significantly relieves symptoms of chronic prostatitis and pain syndrome. The absence of unwanted side effects, significant changes in clinical and biochemical blood and urine parameters evidences for good tolerance and safety of the drug. Thus, rectal suppositories vitaprost plus can be recommended for treatment of chronic bacterial prostatitis caused by both gram-positive and gram-negative bacteria in patients of different age and clinical symptoms.
Lopatkin
N A
NA
Kamalov
A A
AA
Mazo
E B
EB
Kozdoba
A S
AS
Popov
S V
SV
Efremov
E A
EA
Dorofeev
S D
SD
Mel'nik
Ia I
IaI
Okhobotov
D A
DA
D000285:Administration, Rectal; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001826:Body Fluids / Q000166:cytology / Q000382:microbiology; D004338:Drug Combinations; D024841:Fluoroquinolones / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007958:Leukocyte Count; D007962:Leukocytes / Q000166:cytology; D008297:Male; D010146:Pain / Q000209:etiology / Q000517:prevention & control; D010455:Peptides / Q000008:administration & dosage / Q000627:therapeutic use*; D011467:Prostate / Q000378:metabolism / Q000382:microbiology; D011472:Prostatitis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology; D011788:Quality of Life; D012720:Severity of Illness Index; D013488:Suppositories; D016896:Treatment Outcome; D014555:Urination Disorders / Q000209:etiology / Q000517:prevention & control
D000890:Anti-Infective Agents; D004338:Drug Combinations; D024841:Fluoroquinolones; D010455:Peptides; D013488:Suppositories; C524164:Vitaprost; C053091:lomefloxacin